Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Enliven Therapeutics Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY). Enlive...

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)

Enliven Therapeutics ( ($ELVN) ) just unveiled an announcement. Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2026,...

Enliven Therapeutics Expands Authorized Shares After Stockholder Vote

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Enliven Therapeutics, with a price target of $62.00. Accor...

Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Molecular Partners (MOLN), Enliven Therapeutics (ELV...

Market Cap	$1.12B	P/E Ratio	N/A
52W High	$48.53	52W Low	$14.79
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	75.8%
Overall Score	53	Value Score	60
Quality Score	39	Technical Score	60

EPS Current Est	$-1.57	EPS Next Est	$-1.71
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELVN	$40.36	+9.08%	5.10M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELVN	$40.36	+9.1%	5.10M
3
4
5
6

ELVN

ELVN

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Enliven Therapeutics Inc. Data in Excel

Get Enliven Therapeutics Inc. Data in Excel